Sanofi has agreed to acquire haemophilia specialist Bioverativ for US$105 per share, equating to a deal value of US$11.6 B, and represents a sizeable premium of 64% on Bioverativ’s stock price before the deal was announced. It is the biggest deal for Sanofi since the acquisition of Genzyme in 2010. The acquisition boosts Sanofi’s marketed product portfolio by granting access to Bioverativ’s established haemophilia products, Eloctate® (recombinant anti-haemophilic factor, Fc fusion protein) and Alprolix® (recombinant coagulation factor IX, Fc fusion protein), and could help progress the development of Sanofi’s own RNAi haemophila therapy, fitusiran.